Finland Fimea · July 14, 2026

Fimea initiates HTA assessment of new hospital medicine tarlatamab

Original title: Fimea käynnistää HTA-arvioinnin uudesta sairaalalääkkeestä tarlatamabi

Fimea has initiated a health technology assessment for the hospital medicine tarlatamab.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement Finland Health technology assessmentPharmaceuticals
Read the official source ↗

Published by Finland Fimea. HealthSignal links to the original document; the summary above is extracted from the source text.